Journal article
The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE”
P Savas, ZL Teo, C Lefevre, C Flensburg, F Caramia, K Alsop, M Mansour, PA Francis, HA Thorne, MJ Silva, N Kanu, M Dietzen, A Rowan, M Kschischo, S Fox, DD Bowtell, SJ Dawson, TP Speed, C Swanton, S Loi
Plos Medicine | PUBLIC LIBRARY SCIENCE | Published : 2016
Abstract
Background: Understanding the cancer genome is seen as a key step in improving outcomes for cancer patients. Genomic assays are emerging as a possible avenue to personalised medicine in breast cancer. However, evolution of the cancer genome during the natural history of breast cancer is largely unknown, as is the profile of disease at death. We sought to study in detail these aspects of advanced breast cancers that have resulted in lethal disease. Methods and Findings: Three patients with oestrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and one patient with triple negative breast cancer underwent rapid autopsy as part of an institutiona..
View full abstractRelated Projects (1)
Grants
Awarded by Medical Research Council
Funding Acknowledgements
This work was supported by the National Breast Cancer Foundation (NBCF, http://nbcf.org.au/) of Australia, the Breast Cancer Research Foundation (BCRF, https://www.bcrfcure.org/), New York, a UK Medical Research Council grant (UKMRC, MR/FC001169/1), and the Francis Crick Institute (https://www.crick.ac.uk/), which receives its core funding from Cancer Research UK (FC001169, http://www.cancerresearchuk.org/), the UKMRC (FC001169, http://www.mrc.ac.uk/), and the Wellcome Trust (FC001169, https://wellcome.ac.uk/). PS is supported by National Health and Medical Research Council of Australia (NHMRC, https://www.nhmrc.gov.au), NBCF, and Cancer Therapeutics CRC (https://www.cancercrc.com/) post-graduate scholarships. The kConFab Clinical Follow-Up Study is supported by the NHMRC, NBCF, Cancer Australia (https://canceraustralia.gov.au/), and the National Institutes of Health (https://www.nih.gov/). kConFab is supported by NBCF, previously the NHMRC, the Cancer Councils of Queensland (https://cancerqld.org.au/), New South Wales (http://www.cancercouncil.com.au/), Victoria (http://www.cancervic.org.au/), Tasmania (http://www.cancertas.org.au/), and South Australia (https://www.cancersa.org.au/), and the Cancer Foundation of Western Australia (https://www.cancerwa.asn.au/). SJD is supported by a NBCF and Victorian Cancer Agency (http://www.victoriancanceragency.org.au/) Fellowship. TPS is supported by a NHMRC Program Grant (1054618). CS is the Royal Society Napier Research Professor and is funded by Cancer Research UK (TRACERx), the Cancer Research UK Lung Cancer Centre of Excellence (http://www.cruklungcentre.org/), Stand Up 2 Cancer (SU2C, http://www.standup2cancer.org/), the Rosetrees Trust (http://www.rosetreestrust.co.uk/), NovoNordisk Foundation (ID 16584, http://novonordiskfonden.dk/), the Prostate Cancer Foundation (https://www.pcf.org), BCRF, and the European Research Council (THESEUS, https://erc.europa.eu/). Support was provided to CS by the National Institute for Health Research (http://www.nihr.ac.uk/), the University College London Hospitals Biomedical Research Centre (http://www.uclhospitals.brc.nihr.ac.uk/), and the Cancer Research UK University College London Experimental Cancer Medicine Centre (http://www.ctc.ucl.ac.uk/). SL is supported by the John Colebatch Cancer Council of Victoria Clinical Fellowship (http://www.cancervic.org.au/) and the NHMRC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.